On October 22, 2019 Systems Oncology, LLC ("SO") and The Pritzker Organization, LLC ("TPO") reported that Pritzker Family Business Interests advised by TPO have invested in the first closing of SO’s Series B round (Press release, Systems Oncology, OCT 22, 2019, View Source [SID1234542419]). The funding will be used to invest in both discovery research and pre-clinical development to evolve SO’s rapidly expanding pipeline of innovative cancer therapeutics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Systems Oncology leverages big data and AI to discover novel scientific insights into cancer biology. These therapeutic insights are then applied to build therapeutic programs. Specifically, SO’s ExpansiveAI discovery engine allows scientists to integrate and translate big data from hundreds of scientific sources into intelligently linked scientific knowledge, making it possible to uncover truly unique therapeutic opportunities. This cognitive computing platform integrates and connects multiple different kinds of data into multidimensional models, which in turn allows for unprecedented scale and efficiency in applying machine learning to mine trillions of biomedical relationships. This engine enables SO to explore a massive universe of therapeutic opportunities many orders of magnitude more expansive than the human mind can imagine.

"We are honored by the investment from The Pritzker Organization and look forward to them joining us with a seat on our Board of Directors," said Dr. Spyro Mousses, CEO of Systems Oncology. "TPO’s investment is a prestigious recognition for the potential SO has to transform drug discovery and development with AI. They bring a wealth of experience investing in and growing companies and will help us continue to grow for years to come and fulfill our commitment to bring forward breakthrough oncology therapeutics for unmet patient needs."

"We are very excited about the potential for Systems Oncology’s combination of leading-edge AI and outstanding clinical expertise to produce novel cancer therapies," said Joseph Gleberman, TPO Managing Director.

On October 22, 2019 Bristol-Myers Squibb Company (NYSE: BMY) reported that CheckMate -9LA, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) given concomitantly with two cycles of chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC), met its primary endpoint of superior overall survival (OS) at a pre-specified interim analysis (Press release, Bristol-Myers Squibb, OCT 22, 2019, View Source [SID1234542396]). The comparator in this study was chemotherapy alone for up to four cycles followed by optional maintenance therapy. The safety profile of Opdivo plus low-dose Yervoy and two cycles of chemotherapy in CheckMate -9LA was reflective of the known safety profiles of the immunotherapy and chemotherapy components in first-line NSCLC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited by the CheckMate -9LA results, which demonstrate the potential of Opdivo plus low-dose Yervoy to provide a survival benefit to patients with non-small cell lung cancer in the first-line setting when administered concomitantly with a limited course of chemotherapy," said Fouad Namouni, M.D., head, Oncology Development, Bristol-Myers Squibb. "These results build on the benefit the combination of Opdivo plus Yervoy has previously shown in first-line melanoma, renal cell carcinoma and most recently lung cancer, and may provide a new therapeutic option for patients."

The company will complete a full evaluation of the CheckMate -9LA data and looks forward to presenting these results at an upcoming congress and sharing them with regulatory authorities.

On October 22, 2019 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, reported that it will participate in the Jefferies 2019 London Healthcare Conference on November 20 & 21 in London (United Kingdom) (Press release, Transgene, OCT 22, 2019, View Source [SID1234542417]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The management will meet with leading European Healthcare investors to present its innovative immunotherapy portfolio and detail the promising clinical results obtained with the combination regimen of TG4001 in HPV-positive cancers.

On October 22, 2019 Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, reported that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2019 to report its third quarter 2019 financial results and provide a corporate update (Press release, Moderna Therapeutics, OCT 22, 2019, View Source [SID1234542416]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international), and refer to conference ID 6287715. A webcast of the call will also be available under "Events and Presentations" in the Investors section of the Moderna website at View Source The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for 30 days following the call.

On October 22, 2019 Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), reported it will be presenting at the BIO Investor Forum in San Francisco (Press release, Oragenics, OCT 22, 2019, View Source [SID1234542415]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will present to investors on October 23, 2019, at 2:30 PM ET in the Yorkshire Room of Westin St. Francis in San Francisco. The BIO Investor Forum will be held October 22-23, 2019.

Further details of the company’s financial filings can be found by accessing the United States Securities and Exchange Commission website at www.sec.gov.

About AG013

AG013, which has been granted Fast Track designation with the U.S. Food and Drug Administration and orphan drug status in Europe, is an ActoBiotics therapeutic candidate formulated to deliver the therapeutic molecule Trefoil Factor 1 to the mucosal tissues in the oral cavity in a convenient oral rinsing solution. Trefoil Factors are a class of peptides involved in the protection of gastrointestinal tissues against mucosal damage and play an important role in subsequent repair. The compound was designed by the company’s strategic partner, ActoBio Therapeutics, Inc., a wholly-owned subsidiary of Intrexon Corporation (NYSE: XON).

About Lantibiotics

Lantibiotics are a class of antibiotic compounds with novel mechanism of action, prized for their ability to overcome antibiotic-resistant infections. With resistant strains on the rise, particularly healthcare-acquired infections (HAI), the need for these potent lantibiotic agents is critical. Oragenics is pursuing the commercial-scale production of a lantibiotic for use as an antimicrobial.